Clinical Trials Logo

Filter by:
NCT ID: NCT06334887 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

esTOCma, an App Used by Teachers: an RCT

Start date: February 26, 2024
Phase: N/A
Study type: Interventional

The aim of the present study is to assess the efficacy of a mobile application called esTOCma in promoting mental health literacy, reducing stigmatizing attitudes related to the Obsessive-Compulsive Disorder (OCD) and improving teachers' confidence in dealing with students that might have OCD. A parallel, randomized controlled trial with two conditions (experimental and control group) will be carried out in a sample of teachers that work in primary and secondary education. Pre-post changes will be assessed. Experimental group will use the app until they finish it (within a set period of 10 days), whereas control group will do nothing for 10 days. Primarily, it is expected that after the use of the app, participants will show an improvement in OCD-related literacy, stigmatizing attitudes, desired social distance and their comfort, confidence and perceived ability in teaching and handling students with OCD. Secondarily, the investigators hypothesize that experimental group might show a reduction in obsessive-compulsive symptoms.

NCT ID: NCT06334575 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

3TR-ICS-COPD
Start date: July 2024
Phase: Phase 4
Study type: Interventional

The 3TR-ICS COPD study is an international, multicentre, randomized, parallel, controlled study that will recruit clinically stable former smokers COPD patients (with no exacerbations in the previous 8 weeks) on treatment with dual long-acting bronchodilators (LABA+LAMA), minimum 8 weeks of usage, not receiving ICS (either naïve or > 3 months since last usage). The overall objective of this clinical trial is to identify the molecular signatures associated with the molecular response to ICS treatment in patients with COPD stratified by the levels of circulating eosinophils, and the potential influence of the pulmonary microbiome

NCT ID: NCT06334458 Active, not recruiting - Pancreatic Cancer Clinical Trials

Epigenomic and Machine Learning Models to Predict Pancreatic Cancer

IMAGene
Start date: February 3, 2023
Phase: N/A
Study type: Interventional

The goal of the multicentric and interdisciplinary IMAGene project is to pursue early diagnosis for Pancreatic Cancers in high-risk asymptomatic subject groups, by developing and validating a comprehensive cancer risk prediction algorithm (CRPA) as a clinical support tool to calculate a personalized risk profile. The study is a longitudinal, non-randomized exploratory clinical study. A total of 170 asymptomatic first-degree relatives of PC patients.

NCT ID: NCT06334159 Recruiting - Bone Resorption Clinical Trials

Guided Bone Regeneration Using Fixed vs Non-Fixed Resorbable Collagen Membranes

Start date: November 5, 2020
Phase: N/A
Study type: Interventional

The aim of this clinical trial is to compare the horizontal bone gain when grafting a bone substitute with non fixed resorbable collagen membranes (control group), versus fixed resorbable collagen membranes (test group) in resorbed ridges requiring Guided Bone Regeneration (GBR) to facilitate implant placement at 6 months.

NCT ID: NCT06333002 Active, not recruiting - Clinical trials for Acute Hypoxemic Respiratory Failure

Machine Learning Model to Predict Outcome and Duration of Mechanical Ventilation in Acute Hypoxemic Respiratory Failure

MEMORIAL
Start date: March 19, 2024
Phase:
Study type: Observational

Acute hypoxemic respiratory failure (AHRF) is the most common cause of admission in the intensive care units (UCIs) worldwide. We will assess the value of machine learning (ML) techniques for early prediction of ICU death and prolonged duration (>7 days) of mechanical ventilation (MV) in 1,241 patients enrolled in the PANDORA (Prevalence AND Outcome of acute Respiratory fAilure) Study in Spain. The study was registered with ClinicalTrials.gov (NCT03145974). Our aim is to evaluate the minimum number of variables models using logistic regression and four supervised ML algorithms: Random Forest, Extreme Gradient Boosting, Support Vector Machine and Multilayer Perceptron.

NCT ID: NCT06332365 Completed - Oral Lichen Planus Clinical Trials

Evaluating Treatment Efficacy in Oral Lichen Planus: The Role of Salivary Biomarkers

salivaLichen
Start date: January 3, 2022
Phase: N/A
Study type: Interventional

Lichen planus, a chronic autoimmune mucocutaneous disorder, affects 0.5% to 2.2% of diverse populations. The treatment for oral lichen planus (OLP) includes a range of options, both topical and systemic therapies. Recent research has highlighted the potential of hyaluronic acid as a drug alternative, potentially offering effective management for OLP and alleviating the discomfort of this chronic condition. The objective was to assess the impact of topical hyaluronic acid on salivary oxidative stress markers in individuals suffering from oral lichen planus

NCT ID: NCT06332183 Recruiting - Clinical trials for Erdheim-Chester Disease

GWAS and EWAS in Patients With Erdheim-Chester Disease

Start date: July 17, 2019
Phase:
Study type: Observational

Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the condition are still unknown, and although some mutations in genes involved in cell proliferation have been identified, other factors may be involved. Susceptibility to developing rare diseases like ECD is typically associated with genetic factors, including DNA polymorphisms and epigenetic modifications. This study aims to analyze the entire genome of a large cohort of patients with ECD and healthy controls to determine whether there are polymorphisms and epigenetic variants associated with susceptibility to developing the disease. The study could thus clarify the genetic predisposition to ECD development, provide insights into disease pathogenic mechanisms, and identify proteins or cellular mechanisms potentially targeted by specific treatments.

NCT ID: NCT06331871 Recruiting - Clinical trials for Ultrasound-Guided Percutaneous Electrical Nerve Stimulation

Effectiveness of US-PENS for Patients With Post-surgical Shoulder Pain

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The aim of this clinical trial was to demonstrate the effectiveness of the application of ultrasound-guided percutaneous nerve stimulation (US-PENS) directed at the axillary nerve and the suprascapular nerve, in patients with post-surgical shoulder pain. This is a randomized, longitudinal, prospective and quasi-experimental clinical trial in which a total of 70 patients divided into two groups; physiotherapy protocol group (n=35) and experimental group to which the same protocol was practiced and a US-PENS session was added (n=35). The intervention and follow-up period of the participants took place over 12 weeks.

NCT ID: NCT06331832 No longer available - Clinical trials for Relapsed/Refractory Non-Hodgkin Lymphomas

Expanded Access of Imvotamab (IGM-2323) in Patients With R/R NHL

Start date: n/a
Phase:
Study type: Expanded Access

Expanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.

NCT ID: NCT06331598 Recruiting - Solid Tumors Clinical Trials

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

IMperator
Start date: July 30, 2024
Phase: Phase 2
Study type: Interventional

This study is being conducted to evaluate efficacy parameters (disease free survival [DFS] and overall survival [OS]) of atezolizumab and atezolizumab in combination with tiragolumab in TMB-H or MSI-H as adjuvant treatment after standard radical intended treatment in participants with intermediate-high risk of recurrence.